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Introduction: Diabetes mellitus (DM) is a leading cause of morbidity and 
mortality all over the world, and the main cause of the mortality is cardiovascular 
complications. Such diabetic cardiovascular complications include coronary heart 
disease, cardiac autonomic neuropathy and ventricular dysfunction. Furthermore, 
DM is associated with electrolyte disturbances such as those involving potassium, 
calcium and magnesium (Mg2+). Among these electrolyte disturbances 
hypomagnesemia is common in diabetes and is associated with increased 
cardiovascular risk. Recent evidence has shown that Mg2+ supplementation can 
prevent cardiac autonomic dysfunction and improve ventricular compliance in acute 
DM. However, the underlying mechanisms of Mg2+ action and Mg2+ effects in chronic 
DM are unknown. Therefore, the present study explored the effects of Mg2+ 
administration and its possible mechanisms of action in chronic streptozotocin (STZ) 
induced diabetic rats.  
 
Methods: Adult male Wistar rats were injected intraperitoneally (i.p) once with 
either STZ (50 mg/Kg body weight) or the STZ vehicle (citrate buffer). The rats were 
then injected i.p once daily with either magnesium sulphate (MgSO4; 270 mg/Kg 
body weight) or the MgSO4 vehicle (normal saline) for 28 consecutive days. Blood 
glucose and body weight were measured throughout the period of the study. On day 
28 of the experiments, in-vivo heart rate variability (HRV) parameters were 
measured to assess cardiac autonomic function using tail pulse plethysmography. 
Orthostatic stress was induced by tilting the animals from flat position to 70° head-up 
position. Ex-vivo hemodynamic and electrocardiograph (ECG) measurements were 
performed on a Langendorff perfusion system. Histological studies of ventricular 
tissue were performed using haematoxylin-eosin and Masson’s trichrome staining. 
Western blot analyses of the cardiac autonomic presynaptic marker (synaptophysin) 
and of the mitochondrial marker of oxidative stress (ATP5A) were performed on right 




Results: STZ treatment significantly increased the blood glucose level and 
decreased the body weight, and these STZ effects were not prevented by Mg2+ 
treatment. Diabetes decreased the root mean square differences of successive 
normal-to-normal intervals (RMSSD) and increased the low frequency (LF) /high 
frequency (HF) power ratio, which are both indicative of abnormal HRV. These 
diabetes effects on HRV parameters were significantly prevented by Mg2+ treatments 
(P < 0.05, STZ+Mg vs. STZ). DM also reduced both the heart rate and orthostatic 
stress-induced tachycardia, and these effects were reversed by Mg2+ treatment (P < 
0.05, STZ+Mg vs. STZ). 
DM also decreased the left ventricular (LV) developed pressure and the maximal 
rate of LV pressure increase (+dP/dt), and these diabetic effects were prevented by 
Mg2+ treatment (P < 0.05, STZ+Mg vs. STZ). DM also decreased the maximal rate of 
LV pressure decline (-dP/dt) and the rate pressure product, but these parameters 
were not improved by Mg2+ treatment. DM and Mg2+ treatment did not affect the ECG 
waveforms and the coronary flow rate in all groups. Histologically, there were no 
differences in ventricular cardiomyocyte width or in the extent of interstitial fibrosis in 
all groups. Western blot analysis qualitatively showed a decrease in the expression 
of synaptophysin in DM that was prevented by Mg2+ treatment. Neither DM nor Mg2+ 
treatment altered ATP5A expression. The plasma Mg2+ concentration was not altered 
by DM or Mg2+ treatment. 
 
Conclusion: This study showed that Mg2+ treatment prevented cardiac 
autonomic dysfunction and improved hemodynamic function impairment in chronic 
DM. Based on the expression of synaptophysin, the mechanism through which Mg2+ 
improved cardiac autonomic function could involve the prevention of synaptic 
degradation in diabetes. The effects of Mg2+ on hemodynamic impairment in diabetes 
seemed to be unrelated to the Mg2+ effects on the cardiac histological structure or on 
the changes in coronary perfusion. Moreover, the overall effects of Mg2+ in diabetes 
were independent of its effects on the blood glucose level or the alteration of plasma 
Mg2+ level. Thus, Mg2+ treatment may have long-lasting therapeutic effects on 
ventricular dysfunction and cardiac autonomic impairment in chronic diabetes, but 
further studies are needed to explore the precise underlying mechanisms.
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Chapter 1: Introduction 
 
Diabetes mellitus (DM) is a rapidly growing metabolic disorder world-wide and is a 
one of the main leading causes of morbidity and mortality (Guariguata et al. 2011). 
DM affected 382 million adults world-wide by 2013, and is projected to increase to 
592 million by 2035 (Guariguata et al. 2014). Therefore, because of its increased 
incidence globally, DM can be considered an epidemic chronic disease (Wild et al. 
2004). In Africa, the number of diabetic patients in 2010 was 12.1 million and is 
projected to rise to 23.9 million by 2030 (Hall et al. 2011). Furthermore, the 
prevalence of DM in developing countries like South Africa is currently approximately 
9% (Bertram et al. 2013), and projected to reach approximately 69% by 2030 (Shaw 
et al. 2010). As a result, DM creates substantial economic burden in many regions, 
especially in the African continent. The economic burden of DM in the developing 
countries is mainly related to the cost of disease management and patients’ 
disability, both of which result in loss of productivity in the community (Kirigia et al. 
2009). 
DM is a metabolic condition in which there is insulin deficiency, insulin resistance or 
both. The pathogenic processes involved in DM include the destruction of insulin-
producing beta cells of the pancreas and resistance to insulin action at cellular level 
that lead to hyperglycaemia. In addition to hyperglycaemia, insulin deficiency also 
leads to other abnormalities in the metabolism of lipid and proteins, all of which have 
adverse effects on tissues (Alberti and Zimmet 1998, Kerner and Bruckel 2014).  
Globally, DM is considered the fifth leading cause of death, following the other 
common conditions such as infectious diseases and cancer (Roglic et al. 2005). The 
main causes of death in DM include acute life-threatening complications such as 
hypoglycaemia, hyperglycaemia with ketoacidosis or non-ketotic hyperosmolar 
conditions, as well as long-term complications that involve multiple body systems. 
The multi-system complications include cardiovascular diseases (CVD), eye, renal 
problems, gastrointestinal, and neurological damage. Among these complications, 
CVD account for nearly half of diabetic complications (Hobbs 2006, Rao Kondapally 
Seshasai et al. 2011). In addition, most of diabetic morbidity and mortality are due to 
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CVD (Soedamah-Muthu et al. 2006). Diabetic patients with CVD have a poorer 
prognosis than diabetic patients without CVD (Smith, Marcus, and Serokman 1984). 
Moreover, pathological and epidemiological studies have shown that DM is an 
independent risk factor for CVD (Wilson et al. 1998).  
Diabetic cardiovascular complications include coronary artery disease (CAD), 
diabetic cardiac autonomic neuropathy (DCAN), diabetic cardiomyopathy (DCM), 
and other cardiac degenerative conditions. According to American Heart Association, 
DM is the main risk factor for CVD besides hypertension, dyslipidaemia, and 
smoking (Grundy et al. 1999). Diabetic CVD occur as a result of metabolic, 
structural, and electrical changes in the heart and blood vessels. These 
derangements cause cellular changes that leads to pathological remodelling in the 
cardiovascular tissue (Eguchi et al. 2012). The pathological remodelling process is 
further compound by disturbances in electrolytes that are common in diabetes, such 
as those involving calcium (Ca2+), potassium (K+), and magnesium (Mg2+). 
Electrolyte disturbances in DM have been linked to the impairment of excitation-
contraction coupling of the heart (Marks 2003), arrhythmogenesis (Del Gobbo et al. 
2012), and atherosclerosis (Atabek et al. 2006). Among these electrolyte disorders, 
hypomagnesemia is frequent in patients with DM (Pham et al. 2007). Furthermore, 
DM is an independent risk factor of hypomagnesemia in elderly patients (Liamis et 
al. 2013). In addition, hypomagnesemia has been implicated in the pathogenesis of 
diabetic complications, including CVD (Chetan P. Hans 2002).  
Mg2+ treatment in DM has been proposed to improve blood glucose level, oxidative 
stress damage, insulin sensitivity, and prevent development of diabetic complications 
(Barbagallo et al. 1999, Nagai and Ito 2013, Rodriguez-Moran and Guerrero-Romero 
2003). Moreover, a recent study in acute diabetic model shown that Mg2+ treatment 
attenuates cardiac autonomic dysfunction and improves ventricular compliance 
(Amoni et al. 2016).These Mg2+ effects were shown to be independent on its effects 
on hyperglycaemia, hyperlipidaemia, and were unrelated to changes in plasma or 
tissue Mg2+ levels. However, these Mg2+ effects remain unclear whether they are 
sustained in chronic DM. In addition, the underlying mechanisms are unclear.  
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Chapter 2: Literature review 
 
2.1 Diabetes mellitus and cardiovascular disease  
DM is a complex metabolic disorder characterized by impaired production of insulin 
or resistance to insulin action at cellular level. Typically, diabetes is diagnosed when 
fasting blood glucose ≥ 7 mmol /l, random plasma glucose ≥ 11.1 mmol /l, glycated 
haemoglobin A1c (Hb A1c) ≥ 48 mmol /mol or oral blood glucose tolerance test ≥ 
11.1 mmol /l (Association 2014, Craig, Hattersley, and Donaghue 2009). According 
to American Heart Association (2014), DM is classified mainly into two types: insulin-
dependent DM (type 1) and non-insulin dependent DM (type 2). Type 1 DM 
constitute 5-10 % of diagnosed diabetic patients, and mainly occurs due to 
autoimmune destruction of pancreatic beta cell. About 90-95 % of diabetic patients 
belong to type 2 DM, which is mainly due to insulin resistance. In type 2 DM, multiple 
genetic factors and obesity have been linked to insulin resistance and beta cell 
defects (Alberti and Zimmet 1998, Rayburn 1997). 
Several metabolic derangements in DM predispose to cardiovascular complications. 
Hyperglycaemia mediates cellular injury through the activation of alternative 
glycolysis biochemical pathways. Such pathways include polyol pathway flux, 
increased hexosamine pathway flux, and activation of protein kinase C isoforms. 
These alternative biochemical pathways lead to impairment of cellular energy 
utilization and cardiovascular function (Davidoff et al. 2004, Mokuda et al. 1990, 
Robertson 2004). There is also hyperglycaemia- induced mitochondrial 
overproduction of free radicals, which in turn induces cardiovascular tissue damage 
due to oxidative stress (Brownlee 2001). Hyperglycaemia also leads to the formation 
of advanced glycation end-products (AGEs), which interfere with cardiovascular 
tissue integrity. DM also causes electrolyte disorders and acid-base disorders such 
as ketoacidosis, lactic acidosis, and hyperchloremic acidosis (Sotirakopoulos et al. 
2012). Moreover, DM induces dyslipidaemia  where there is elevated triglycerides, 
decreased high density lipoprotein, and increased low density lipoprotein (Taskinen 
2003). Dyslipidaemia  also leads to oxidation of lipoproteins and formation of pro-
atherogenic glycoxidation products (Lopes-Virella et al. 2005). 
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2.2 Diabetic cardiovascular complications and their 
underlying mechanisms 
 
2.2.1 Diabetic cardiomyopathy 
Diabetic cardiomyopathy (DCM) is a disease condition caused by DM-induced 
structural and functional abnormalities in the myocardium that occur independently of 
other contributing factors such as CAD or hypertension. DCM is a leading cause of 
heart failure (Hayat et al. 2004), whereas DM is an independent risk factor for heart 
failure. The evidence supporting these findings has been reported in several studies, 
including the Framingham Study (Kannel, Hjortland, and Castelli 1974), 
Cardiovascular Health Study (Gottdiener et al. 2000), and United Kingdom 
Prospective Diabetic Study (Stratton et al. 2000). Clinically, DCM can be assessed 
by non-invasive techniques such as tissue doppler echocardiography, which can 
detect the abnormality even before the onset of symptoms, or by invasive techniques 
such as cardiac cauterization (Hayat et al. 2004). 
The structural changes in DCM include left ventricle (LV) hypertrophy and 
myocardial fibrosis. LV hypertrophy is a consequence of increased LV mass and 
leads to ventricular stiffness and LV dysfunction (Devereux et al. 2000, Levy et al. 
1990). The Strong Heart Study (Devereux et al. 2000) has reported that diabetic 
patients have increased LV mass, wall thickness, and arterial stiffness. 
Cardiac diastolic dysfunction is an initial sign of functional changes in DCM 
(Karamitsos et al. 2007, Raev 1994). Diastolic dysfunction is widely reported in 
diabetic patients (Bouchard et al. 1989, Rajan and Gokhale 2002). Furthermore, 
experimental studies have documented the occurrence of diastolic dysfunction in 
diabetic animal models through echocardiographic measurements (Semeniuk, 
Kryski, and Severson 2002) and isolated heart perfusion experiments (Aasum et al. 
2003). It has been observed that the diastolic dysfunction in DCM precedes systolic 
impairments in diabetic patients and diabetic animal models (Litwin et al. 1990, 
Schannwell et al. 2002). Furthermore, the occurrence of both diastolic dysfunction 
and systolic dysfunction seems to be related to the duration of DM (Shapiro, Howat, 
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and Calter 1981). In addition, the signs of ventricular dysfunction have been 
observed in type 1 DM than in type 2 DM (Lavine 1999).  
 
2.2.1.1 Mechanisms underlying diabetic cardiomyopathy 
The pathogenic mechanisms of DCM are multifactorial. These mechanisms include 
metabolic disturbances, oxidative stress, cardiac remodelling, mitochondrial 
dysfunction, and others (Spector 1998, Tziakas, Chalikias, and Kaski 2005). 
Hyperglycaemia is also a key factor that underlies several metabolic disturbances in 
DCM (Chatham and Seymour 2002). Hyperglycaemia mediates its pathogenic 
effects via several mediators such as oxidative stress and increased formation of 
AGEs.  
2.2.1.1.1 Oxidative stress 
An increase in oxidative stress in the diabetic heart is the main factor in the 
development and advancement of DCM (Cai 2006, Cai et al. 2006, Crespo et al. 
2008). Oxidative stress is a state of imbalance between pro-oxidant and antioxidant 
mechanisms leading to tissue damage (Sies 1997). The oxidative stress occurs due 
to increased production of free radicals such as the reactive oxygen species (ROS) 
and the reactive nitrogen species. The production of free radicals in DM occurs 
through glucose auto-oxidation (which is the main source of free radical production), 
the formation of AGEs, and mitochondrial damage (Bonnefont-Rousselot 2002, 
Ceriello and Motz 2004).  
The mitochondrion is the main source of ROS in DM (Nishikawa et al. 2000). The 
mitochondrion is the organelle responsible for providing the cell with energy via the 
process of oxidative phosphorylation (Neubauer 2007). The mitochondrial adenosine 
triphosphate (ATP) is the main source of energy for cellular metabolism (Schapira 
2006). The ATP production in the mitochondria occurs under activity of ATP 
synthase (F0F1 complex), which is located in the mitochondrial membrane and 
consist of two subunits F0 and F1. The F1 subunit consists of five subunits (α, β, γ, 
δ, and ε), where the β subunit is the catalytic site of the enzyme, while the α subunit 
is the functional nucleotide of the enzyme (Abrahams et al. 1994). DM causes 
changes in the structure and function of mitochondria (Pierce and Dhalla 1985, Shen 
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et al. 2004). This mitochondrial disturbances result in reduction of ATP production 
due to defect in enzymatic activity such as ATP synthase, therefore leading to 
cardiac dysfunction (Pierce and Dhalla 1985). Additionally, a previous study has 
shown a decrease in the ATP synthase activity in diabetic heart that could be 
prevented by metallothionein (Cong et al. 2014). 
DM is also associated with compromised antioxidant defences mechanisms. 
Antioxidant mechanisms include both enzymatic and non-enzymatic components 
that work together to remove free radicals. The enzymatic antioxidants include 
glutathione peroxidase and superoxide dismutase (Baynes 1991, Baynes and 
Thorpe 1999, Saxena et al. 1993), whereas non-enzymatic components include 
vitamins. The study by Patel and colleagues showed that there is a reduction in the 
activity of antioxidant enzymes such as superoxide dismutase in the diabetic heart 
with ventricular dysfunction (Patel, Raghunathan, and Porwal 2014). Therefore, the 
alteration in the activity of antioxidant defence leads to oxidative stress and cell injury 
in DM (Maritim, Sanders, and Watkins 2003). 
2.2.1.1.2 Formation of AGEs 
The formation of AGEs in DM plays a part in the pathogenesis of DCM. The AGEs 
are a group of varied compounds that arise from series irreversible non-enzymatic 
reactions between glucose and proteins (Basta, Schmidt, and De Caterina 2004). 
DCM is characterized by an increase in the deposition of collagen and AGEs in-
between cardiac myofibers, leading to interstitial fibrosis, and around cardiac blood 
vessels leading to perivascular fibrosis. The deposition of collagen and AGEs in the 
heart leads to stiffness of the myocardium, ventricular dysfunction, and eventually 
heart failure (Deluyker, Evens, and Bito 2017,  Regan et al. 1977, van Heerebeek et 
al. 2008). The production of AGEs also causes cellular dysfunction through 
modification of intracellular and extracellular proteins. In addition, AGEs decrease 
endothelial production of nitric oxide, and the reduced bioavailability of nitric oxide 
increases LV diastolic stiffness (Bucala, Tracey, and Cerami 1991, Heymes et al. 
1999). 
AGEs also bind to specific AGE receptors (called RAGE), which are expressed on 
the cell surfaces of cardiac, vascular, and inflammatory cells (Brett et al. 1993, 
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Goldin et al. 2006, Schmidt et al. 1999). The activation of RAGE induces the 
production of ROS (Yan et al. 1994) as well as the modulation of transforming 
growth factors and fibrosis (Striker and Striker 1996). DM induces an increase in the 
expression of RAGE in the cardiomyocyte that leads to modulation of nuclear factors 
and induction of cardiac dysfunction (Aragno et al. 2006). Ma et al.(2009) showed 
that the modulation of RAGE expression prevents diabetes-induced contractile 
dysfunction in diabetic model. The AGEs-RAGE interaction also leads to reduced 
enzymatic activity of sarcoplasmic reticulum in the diabetic heart, and participate to 
impairment in cardiac function (Arai 2002, Bidasee et al. 2004). 
2.2.1.1.3 Cardiac remodelling 
Cardiac remodelling is an important pathogenic factor for DCM and other cardiac 
disturbances. Remodelling refers to alteration in the structure and electrical function 
of the heart. Ventricular structural remodelling occurs as a result of cellular, 
molecular, and interstitial changes in response to cardiac disease or injury (Cohn, 
Ferrari, and Sharpe 2000). The changes in cardiac structure or morphology manifest 
as cardiac cell hypertrophy, cardiac fibrosis, and cell death (Swynghedauw 1999). 
Concentric LV hypertrophy is frequently detected in diabetic patients (Bella et al. 
2001, Devereux et al. 2000), where an increase in the myocardial mass is attributed 
to an increase in cardiomyocyte size. In addition, cardiac fibrosis is a feature of LV 
hypertrophy due to alteration of extracellular matrix. The main collagen deposition 
detected in cardiac fibrosis is collagen type I and III, which lead to impairment of  
ventricular contraction and relaxation (Weber 1997). In DM, the specific factors that 
may be involved in cardiac remodelling include oxidative stress and the generation of 
AGE by-products. Oxidative stress leads to ventricular remodelling through several 
responses, including the modulation of extracellular matrix (King et al. 2003), 
alteration of signalling pathways that lead to cardiac hypertrophy, and apoptosis 
(Cesselli et al. 2001, Takano et al. 2003).  
Diabetic structural remodelling is also compounded by electrolyte disturbances and 
electrical remodelling. DM is associated with cardiac contractile dysfunction due to 
disturbance in the Ca2+ transport system (Ganguly et al. 1983, Luo and Anderson 
2013). Several studies have shown through in-vivo and ex-vivo experiments in 
diabetic rat models that there is an alteration in the Ca2+ homeostasis and Ca2+ 
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signaling in DM (Choi et al. 2002, Ren and Bode 2000, Teshima et al. 2000). A 
consequence of reduced Ca2+ content of sacroplasmic reticulum is the decreased 
release of Ca2+ during ventricular systolic period (Bouchard and Bose 1991, Lagadic-
Gossmann et al. 1996). In addition, Trost et a l. (2002) found that the increased 
expression of sacroplasmic reticulum Ca2+ pump could protect the diabetic heart 
from contractile dysfunction. The other aspect related to Ca2+ that contributes to 
contractile dysfunction in DM is an alteration in the contractile proteins such as the 
activity of Ca2+ ATPase (Dillmann 1980, Takeda et al. 1996). Hamblin et al. (2007) 
also demonstrated that the impaired cardiac function in chronic diabetic rat model 
was associated with alteration in the expression of several cardiac proteins such as 
myosin and is accompanied with an increase in oxidative stress.  
DM also induces electrolyte imbalances and alteration in the electrical properties of 
the cardiomyocyte. Such changes comprise cellular ion homeostasis and the 
generation of normal action potentials (Jourdon and Feuvray 1993, Shimoni et al. 
1994). The ionic alterations in cardiac remodelling involve complex disturbance in 
the function and expression of the ion currents (K+, Ca2+ and sodium). These 
alterations in electrolytes impair cardiac repolarization and impair the heart rhythm 
(Akar and Rosenbaum 2003, Cutler, Jeyaraj, and Rosenbaum 2011). Specifically, 
diabetic electrical remodelling of the atrium leads to interatrial conduction defects 
that predispose to atrial fibrillation (Kato et al. 2006), whereas ventricular electrical 
remodelling leads to life threatening arrhythmia such as ventricular tachycardia and 
fibrillation (Coronel et al. 2013, Wang and Hill 2010).  
 
2.2.2 Coronary artery disease  
CAD is a spectrum of conditions caused by pathology in the coronary arteries of the 
heart, and includes myocardial infarction (MI) and angina. DM is independent risk 
factor for CAD (Koskinen et al. 1992). The early diagnosis of CAD in diabetic 
patients is important in order to achieve appropriate and timely treatment. In order to 
promote the early detection, the American Diabetes Association (1998) has 
established screening programmes for CAD in diabetic patients. These programmes 
included old age patients with high blood pressure, and increased lipid profile as well 
as smokers. The diagnostic tools used for these evaluations include resting and 
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exercise electrocardiograph (ECG), echocardiography, and perfusion imaging 
techniques.  
DM increases the incidence of MI by two to three times, and MI in diabetic patients 
have poorer prognosis than in non-diabetic patients (Grundy et al. 1999, Herlitz et al. 
1988). CAD is a leading cause of mortality in patients with DM and accounts for 
nearly 80% of all diabetic mortality (Thom et al. 2006). Despite the advances in 
medical evaluation of CAD, the diabetic patients with CAD have a poor prognosis 
post MI than that in non-diabetic patients. In addition, diabetic patients with MI have 
a higher risk of re-infarction, angina, arrhythmia, and heart failure than in non-
diabetic subjects (Abbott et al. 1988, McGuire et al. 2000). It has been reported by 
Kahn et al. (2012) that the mortality rate is higher in patients with DM following 
percutaneous coronary artery intervention than that in non-diabetic patients. 
Moreover, the extent of coronary arteries involvement is higher in DM, and diabetic 
patients have a higher incidence of multi-vessel disease compared to non-diabetic 
patients (Waller et al. 1980). 
 
2.2.2.1 Mechanisms underlying coronary artery disease in diabetes mellitus 
There are several pathogenic factors predisposing to atherosclerotic CAD in DM. 
Lipid abnormalities are an important atherogenic risk factor (Bakogianni et al. 2001), 
and are significantly related to glycaemic control. Abnormalities of lipid profile in DM 
include elevated triglycerides, increased concentration of low density cholesterol, 
and decreased concentration of high density cholesterol. Hyperlipidaemia leads to 
lipid peroxidation of low density lipoprotein through superoxide-dependant pathways 
that cause free radical production (Kawamura, Heinecke, and Chait 1994). In 
addition, there is an increase in lipid peroxidation by-products such as 
malondialdehyde, which is the principle product of polyunsaturated fatty acid 
peroxidation and has been identified in the serum of diabetic patients. Increased 
levels of malondialdehyde are also associated with the advancement of diabetic 
CAD (Dierckx et al. 2003, Gallou et al. 1993). Dyslipidaemia, together with 
hyperglycaemia and insulin resistance also induce dysfunction of vascular 
endothelial and smooth muscle cells (Renard et al. 2004, Suzuki et al. 2001, 
Williams et al. 1996). Endothelial dysfunction in DM is associated with low levels of 
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nitric oxide and increased levels of endothelin 1 (Eren, Yilmaz, and Aydin 2013). The 
endothelial dysfunction in DM impairs vasodilation due to decreased production of 
vasodilators such as nitric oxide through the inhibition of enzymes involved in the 
synthesis of the vasodilators (Hink et al. 2001). Inflammation is also an important 
pathogenic factor for atherosclerosis in DM, because of an increase in the production 
of inflammatory and pro-inflammatory cytokines (Pickup 2004). In addition, 
disturbances in platelet function and abnormality in coagulation factors contribute to 
CAD pathogenesis (Mansfield, Heywood, and Grant 1996, Vinik et al. 2001). 
Furthermore, hyperglycaemia-induced oxidative damage and formation of AGEs 
have been implicated in atherosclerosis in diabetic patients and the concentration of 
AGEs increase with severity of atherosclerosis (Nakamura et al. 1993). 
  
2.2.3 Diabetic cardiovascular autonomic neuropathy  
DCAN is a frequent form of neuropathy in DM, and it occurs in one fourth of type1 
DM and in one third of type 2 DM patients (Ziegler 1994). Although the prevalence of 
DCAN is increased both with age and with the duration of DM (Low et al. 2004), 
DCAN can also be discovered at the first time of diabetic diagnosis (Vinik, Freeman, 
and Erbas 2003). DCAN is a cause of increased morbidity and mortality in the DM 
because it is accompanied by an increase in the occurrence of silent myocardial 
infarction, cardiac dysrhythmias, and sudden death (Kempler et al. 2002, Ziegler 
1994). In addition, DCAN increases risk of mortality in diabetic patients with previous 
MI (Miettinen et al. 1998).  
The cardiac autonomic nervous system plays a key role in regulating the changes in 
cardiac rhythm and the speed of electrical propagation in the cardiac conduction 
system. Autonomic cardiac innervation includes sympathetic and parasympathetic 
systems. The sympathetic innervation originates from spinal cord thoracic segments, 
whereas the parasympathetic innervation is by vagus nerve (Jamali, Waqar, and 
Gerson 2016). The diabetic autonomic dysfunction in the early stages affects the 
longest autonomic nerves, so the vagus nerve (which is the longest nerve in the 
body and mediates 75% of parasympathetic activity) is affected early. Therefore, 
there is a decrease in the parasympathetic activity in early stage of DM, which leads 
to compensatory of sympathetic activity. In addition, progressive DCAN leads to 
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sympathetic failure in the later stages of DM when the disease becomes clinically 
evident (Pop-Busui et al. 2004, Taskiran et al. 2004). The clinical manifestation of 
DCAN in early stages of DM includes exercise intolerance and resting tachycardia 
due to parasympathetic impairment (Pop-Busui 2012).  
DM also impairs the cardiovascular autonomic regulation of the baroreceptor reflex. 
The arterial baroreceptors are localized in the carotid sinus and aortic arch and are 
stretch sensitive receptors to physiological stimulation and blood pressure changes. 
The afferent nerve fibers of the baroreceptor reflex pass through vagus and 
glossopharyngeal nerve fibers to the central nervous system. The efferent nerve 
fibers pass via autonomic nerves to the blood vessels and heart. High blood 
pressure results in an increase of the vagal nerve stimulation and a decrease in 
sympathetic outflow, resulting in decrease in heart rate (HR), cardiac contractility, 
and peripheral resistance. On the contrary, low blood pressure leads to inhibition of 
vagal activity and increase in sympathetic activity causing increase HR, cardiac 
contractility and peripheral resistance (Kirchheim 1976, La Rovere, Pinna, and 
Raczak 2008). DM is accompanied by impairment in the baroreceptor reflex that is 
often associated with life threating arrhythmia (El-Menyar 2006). The diabetic 
patients with abnormal baroreceptor reflex have an increased risk for morbidity and 
mortality than that in diabetic patients with normal baroreceptor reflex (Ewing, 
Campbell, and Clarke 1980). The diabetic dysfunction in baroreceptor reflex has 
been demonstrated in the diabetic patients (Kaminska et al. 2008, Martiniskova et al. 
2009), and in the experimental diabetic rat model (Dall'Ago et al. 1997, Maeda et al. 
1995).  
The sympathetic-vagal balance of the autonomic system can be evaluated by 
several measurements such as heart rate variability (HRV) and baroreceptor reflex 
sensitivity. There are also other invasive measurement techniques such as 
microneurography and cardiac sympathetic imaging, but HRV and baroreceptor 
reflexes assessments are non-invasive techniques that are widely used to evaluate 
cardiac autonomic innervation (Aubert et al. 1999). Notably, a reduction in HRV is 
one of the initial signs of cardiovascular autonomic neuropathy (Schonauer et al. 
2008). Furthermore, abnormality of HRV in DM represent a higher risk for ventricular 
dysrhythmia, as well as overall cardiovascular morbidity and mortality 
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(Bhagyalakshmi et al. 2007). Therefore, measurement of HRV is a simple test for 
early detection of DCAN, thereby promoting appropriate therapeutic intervention 
(Boulton et al. 2005).  
 
2.2.3.1 The mechanisms underlying diabetic cardiovascular autonomic 
neuropathy 
There are several mechanisms and pathways involved in the pathogenesis of DCAN. 
These include metabolic disturbances, neurovascular insufficiency, autoimmunity, 
and neuro-hormonal disturbances. Hyperglycaemia and its adverse metabolic 
derangements such as oxidative stress, formation of AGEs mentioned above, all 
represent important causes for autonomic neuronal damage (Vinik, Freeman, and 
Erbas 2003). Oxidative stress is a critical pathogenic factor for DCAN. The neuronal 
axons are more susceptible to oxidative stress damage since the axon has a high 
content of mitochondria (Leinninger et al. 2006, Vincent et al. 2004). Furthermore, in 
non-diabetic conditions, mitochondrial ATP synthase has been reported to be 
impaired by oxidative stress damage in the early stages of neurodegenerative 
disorders (Terni et al. 2010). However, the exact role of mitochondrial oxidative 
stress on ATP synthase in DCAN is still unknown.  
Changes in the neuronal ultrastructure or molecular composition in the heart also 
contribute in the pathogenesis of DCAN. Sanyal et al. (2012) showed that there was 
a degradation of parasympathetic nerve endings and a reduction of neurotransmitter 
vesicles in diabetic rats. In addition, Li et al. (2015) documented that the underlying 
mechanism of DCAN involves the remodelling of autonomic nerves through 
derangements in the process of neurotransmitter synthesis. Moreover, Yang and 
Chon (2011), evaluated autonomic nerve protein markers such as synaptophysin 
and demonstrated that there was a reduction in the autonomic nerve density in 
spontaneously diabetic mice. 
 
2.2.4 Electrolyte disturbances in diabetes 
DM is often associated with various electrolyte disturbances such as those of 
potassium, Mg2+, sodium and Ca2+. Electrolytes are an essential for the excitation- 
and contractile activity of the heart, and for maintenance of cardiac function (Marks 
13 
 
2003). Apart from the aspects of electrical remodelling described above, diabetic 
electrolyte disturbances have also been reported to underlie myofilament dysfunction 
in the diabetic heart (Jweied et al. 2005). The dysregulation of ionic channel 
transport and mitochondrial dysfunction also play a role in the electrolyte disorders in 
DM (Heyliger, Prakash, and McNeill 1987, Takeda et al. 1996). Among electrolyte 
disturbances, hypomagnesemia is a common electrolyte disorder in DM with a 
prevalence rate of about 25-30% (Rude 1992).  
 
2.2.4.1 Mg2+ and diabetes 
Mg2+ plays an essential role as a cofactor for various enzymatic reactions involved in 
energy metabolism (Laires, Monteiro, and Bicho 2004). In addition, Mg2+ is an 
important factor for various cellular process such as insulin activity, metabolism of 
glucose, and vascular function (Chetan P. Hans 2002). In non-diabetic conditions, 
low Mg2+ at the cellular level causes an increase production of pro-fibrogenic and 
pro-inflammatory responses (Kurantsin-Mills et al. 1997, Maier et al. 2004, 
Shivakumar 2002). In addition, low level of Mg2+ is associated with reduction in 
enzymatic activity involved in antioxidant process such as glutathione reductase 
(Zhou, Olinescu, and Kummerow 1999).  
Hypomagnesemia in DM is associated with atherosclerosis (Atabek et al. 2006), and 
arrhythmia (Del Gobbo et al. 2012). Hypomagnesemia is also a key factor 
associated with insulin resistance and vascular diseases in DM (Nadler et al. 1993, 
Paolisso and Barbagallo 1997). The mechanism underlying Mg2+ deficiency in DM is 
not completely clarified. The transport channels for Mg2+ include transient receptor 
potential (TRP) channels. Among these TRP channels members, the TRP melastatin 
6 (TRPM6) is responsible for transcellular Mg2+ reabsorption, and is expressed in the 
kidney and intestine (Voets et al. 2004). Lee and collaborators study (Lee et al. 
2006) have shown that the increased Mg2+ loss in DM is associated with an increase 
in the abundance of TRPM6 in the kidney. Another related TRP channel member is 
TRPM7, which is the most sensitive channel for Mg2+ ion and involved in regulation 
of cellular signalling pathways (Penner and Fleig 2007). TRPM7 channel is highly 
expressed in the myocardium and it is essential for cardiac automaticity. In addition, 
the expression of TRPM7 is increases in the hyperglycaemia-induced vascular 
14 
 
endothelial cell injury (Sun et al. 2013). In addition, the osmotic diuresis due to 
glycosuria in DM may also be linked to Mg2+ electrolyte disorders (Liamis et al. 
2014). 
Mg2+ has been shown to activate antioxidant enzymes such as superoxide 
dismutase, catalase and deficiency of magnesium decrease activation of those 
enzymes in the heart (Kumar and Shivakumar 1997). Magnesium sulphate (MgSO4) 
also attenuated oxidative stress by decreasing the production of malondialdehyde in 
sodium metavanadate-induced lipid peroxidation in non-diabetic rat model (Scibior, 
Golebiowska, and Niedzwiecka 2013). In addition, magnesium valproate also 
decreased LV hypertrophy and fibrosis in DM and these effects were mediated by 
reduction of the oxidative stress biomarkers levels in the heart of diabetic rat model 
(Patel, Raghunathan, and Porwal 2014).  
 
2.2.5 Problem statement  
There is controversy about the role of Mg2+ on blood glucose level and 
hyperlipidaemia in DM as well as on diabetic cardiovascular complications such as 
cardiac autonomic neuropathy, myocardial fibrosis and ventricular dysfunction. One 
debatable aspect regards the effect of Mg2+ on blood glucose level and 
hyperlipidaemia in DM. Chronic oral Mg2+ supplementation in type 2 diabetic patients 
has been reported to reduce blood glucose and to modulate the lipid profile (Patel, 
Raghunathan, and Porwal 2014, Solati et al. 2014, Song et al. 2006). A previous 
study on diabetic patients with hypomagnesemia found that chronic Mg2+ 
supplementation enhanced insulin sensitivity and metabolic control (Rodriguez-
Moran and Guerrero-Romero 2003). The effect of Mg2+ on blood glucose may be 
linked to the circumstance that Mg2+ is an important cofactor for glucose transport 
and it is involved in several enzymatic reactions in carbohydrate metabolism (Laires, 
Monteiro, and Bicho 2004). However, other studies have found no significant effects 
of Mg2+ supplementation on blood glucose and lipid profile in DM (de Valk et al. 
1998, Lal et al. 2003). Although chronic Mg2+ administration could modulate lipid 
profile in type 1 DM (Soltani, Keshavarz, and Dehpour 2007), there is no evidence 
reported on effect of the Mg2+ on blood glucose level in this type of DM.  
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2.2.6 Significance of the present study  
The effects of Mg2+ on the diabetic cardiovascular complications have received a 
growing interest. Previously, Mg2+ treatment has been reported to improve 
hyperglycaemia and dyslipidaemia in DM (Patel, Raghunathan, and Porwal 2014, 
Solati et al. 2014, Song et al. 2006). Furthermore, a recent study in an acute model 
of streptozotocin (STZ) induced diabetic rat found that Mg2+ treatment prevents the 
impairment of HRV. In addition, Mg2+ also improved left ventricular compliance, but 
there were no effects of Mg2+ administration on blood glucose level, lipid profile or 
Mg2+ level in plasma and tissue (Amoni et al. 2016). However, such effects of Mg2+ 
need to be explored in chronic diabetes to distinguish chronic effects from short term 
effects. Moreover, there is incomplete evidence about the underlying mechanisms of 
these Mg2+ effects. Therefore, the current study could determine whether these Mg2+ 
effects are sustained in chronic diabetic cardiovascular complications. In addition, 


















Hypothesis   
 
The hypothesis of this study is that the cardiovascular dysfunction caused by chronic 
DM can be attenuated with Mg2+ treatment via mechanisms involving structural- and 
biochemical alterations.  
 
Aim of the study  
 
To explore the effects of Mg2+ treatment on chronic diabetic cardiovascular 
complications and clarify possible underlying mechanisms. 
 
Specific objectives  
1- To evaluate the effect of Mg2+ treatment on chronic diabetic cardiac autonomic 
neuropathy, ventricular function and myocardial morphological changes.  












Chapter 3: Materials and methods 
  
3.1 Ethical statement 
The experimental procedures were approved by the Animal Ethics committee of the 
Faculty of Health Sciences, University of Cape Town (Protocol Ref AEC 014/014, 
see approval letter in Appendix 1), and were performed in compliance with the Guide 
for the Care and Use of Laboratory Animals (National Research Council, National 
Academy Press, 2011). The personnel who performed procedures on animal 
experiments were authorised by the South Africa Veterinary Council.  
 
3.2 Animals and animal care 
Adult male Wistar rats (weighting 250-300 g) were used in this study. The Wistar rat 
strain is the most widely used in cardiovascular research (Berardi et al. 2011, van 
Dijk et al. 2011). In addition, a previous study in our laboratory successfully 
established an acute diabetic model using the Wistar strain (Amoni et al. 2016), so 
for continuity, the same rat strain was used for chronic diabetic model. The reason 
for the choice of male rats only was to avoid a hormonal cyclic change in the female 
which could affect the blood glucose level or impair cardiac function (Wong et al. 
2013).  
The rats were obtained from Stellenbosch University Research Animal Facility and 
were transferred to the University of Cape Town, Anatomy Building Animal Facility. 
The rats were given two days to adapt to a new environment before starting the 
experimental procedures. The rats were housed in clean cages with wood shaving 
as bedding, and red-rubber tubes were placed in the cages for environmental 
enrichment. To enhance animal socialization, more than one rat was housed per 
cage. The environmental temperature was set at 21-23°C and the light intensity at 
150 Lux, with fixed 12-12 hours light-dark cycle. The rats had a free access to 
standard rat chow (Imbani Nutrition, SA), and water. The welfare of the rats was 




3.3 Treatment protocol 
In this study streptozotocin (STZ; Sigma, SA) was used for induction of DM. STZ (2-
Desoxy-2-3-methyl-3-nitrosoureido-D-glucopyranose) is a broad spectrum antibiotic 
produced by the bacterium Streptomyces achromogens, and is particularly toxic to 
the insulin-producing beta cells of the pancreas through alkylation of the DNA 
(Elsner et al. 2000). The diabetogenic activity of the STZ was initially described in 
1963 (Rakieten, Rakieten, and Nadkarni 1963), and the drug then became a widely 
used chemical for the experimental diabetic induction in rodents (Lenzen 2008, 
Szkudelski 2001). STZ produces a diabetic state that mimics type 1 DM that is 
characterized by hyperglycaemia, polyuria, polydipsia, polyphagia, glycosuria, and 
hypoinsulinemia (Hakim, Patel, and Goyal 1997). In addition, from the disease model 
established in our laboratory, STZ diabetic model also has an evidence of 
hyperlipidaemia, a feature of type 2 DM (Amoni et al. 2016). A moderate dose of the 
STZ (50 mg/kg body weight) can induce non-ketotic diabetes in rats that can survive 
for a long duration such as four weeks without a need for insulin treatment (Miethke 
et al. 1986, Wei et al. 2003). The STZ-induced diabetes is therefore a good model 
for evaluating the pathogenesis of DM and the mechanism of diabetic complications 
(Wu and Yan 2015).  
The experimental rats were divided randomly into four treatment groups described 
below (figure 1), and each rat was identified by a special code.  
1) STZ group: the rats were injected intraperitoneally (i.p) once with STZ (50 mg/kg 
body weight) thereafter, the rats were injected i.p once daily for 28 consecutive days 
with normal saline. 
2) STZ+Mg group: the rats were injected once i.p with STZ (50 mg/kg body weight) 
thereafter, the rats were injected i.p with MgSO4 (270 mg/kg body weight) for 28 
consecutive days. 
3) Control group: the rats were injected i.p with STZ vehicle (citrate buffer) once then 
the rats were injected i.p once daily with normal saline for 28 consecutive days.  
4) Mg group: the rats were injected i.p once with citrate buffer, thereafter, the rats 




STZ was prepared freshly before the time of injection, and was dissolved in 0.1 
mol/L citrate buffer at pH 4.5 (see details in Appendix 2). The rats were starved of 
food for 6 hours before injection in order to increase STZ sensitivity and the uptake 
of STZ by pancreatic β-cell (Chen et al. 2015). Blood glucose levels were measured 
using a glucometer (Accu-Chek, Roche, SA) through tail prick blood samples. The 
rats with random blood glucose levels > 14 mmol/L were considered diabetic.  
The dose of MgSO4 (270 mg /kg body weight) was chosen based on a previous study 
in our laboratory that showed this dose of MgSO4 had a cardioprotective and 
antiarrhythmic effects in a cardiac hypertrophy model (Amoni et al. 2017).  
The rat body weight and the blood glucose levels were measured daily during the 
first week of the study, after which the body weight was measured once every three 
days and the blood glucose was measured once weekly. On day 28, in-vivo HRV 
parameters were measured using tail pulse plethysmography (n= 9-10 rats/group). 
Thereafter, ex-vivo experiments were performed for either hemodynamic and 
electrocardiogram (ECG) assessments on isolated hearts (n= 8-10 rats/groups), or 
the harvesting of the heart tissue for a histological study (n= 5-6 rats/group) and 


















Figure 1: Summary diagram of the experimental protocol. 
STZ: streptozotocin, Mg: magnesium, i.p: intraperitoneal. 
 
3.4 In-vivo heart rate variability measurements  
The standard technique for HRV measurement is an analysis of the RR intervals 
from the ECG. However, the use of tail pulse waveform instead of ECG interval for 
HRV measurement has been validated in other studies, including in our laboratory 
(Amoni et al. 2016, Linder et al. 2014). The advantages of using tail pulse 
plethysmography in rats are that the procedure is non-invasive and that there is no 
need for anaesthesia. Anaesthesia produces sympathetic dysfunction, thereby 
altering the autonomic function of the heart (Shimokawa et al. 1998).  
HRV was measured on day 28 of the experiment using tail pulse plethysmography. 
The recording was done without anaesthesia, but with a rat held in a restrainer. The 
measurements were made in a quiet room with regulated temperature (21-23°C) and 
light intensity in order to avoid stress on the rats. The rats were familiarized with the 
rodent restrainer daily for one week before actual recordings. The piezo-electric 
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pulse transducer (TN1012, AD Instruments, Australia) was placed on the base of the 
rat’s tail on the lateral side of the ventral artery to avoid compression (figure 2 A). 
The transducer was connected to the Power Lab data-acquisition system (AD 
Instruments, Australia). The pulse recording was done for 5-10 minutes while the rat 
was in the flat resting position. To induce orthostatic stress, the restrainer was tilted 
to a 70° angle (figure 2 B), and controlled in this position for recording for an 
additional 5 minutes. The orthostatic stress increases sympathetic reactivity through 
activation of the baroreceptor reflex due to changing the position of the body to 
head-up (Bedette, Santos, and Fontes 2008). HRV parameters were recorded with 
Power Lab data-acquisition system through LabChart Pro 8 software (AD 
Instruments, Australia).  
The HRV data was analysed with the LabChart Pro HRV v.2.0.1 analysis Module 
(AD Instruments, Australia). The HRV detector setting was adjusted to allow all beat 
detection accurately. The recorded trace was scanned manually to exclude all 
ectopic and artefacts from the analysis. The interpretation of HRV parameters was 
performed according to guideline of Task Force of The European Society of 
Cardiology and The North American Society of Pacing and Electrophysiology (1996). 
The HRV parameters were analysed using time domain and frequency domain 
parameters. The time domain parameters included the root mean square differences 
of successive normal-to-normal intervals (RMSSD), whereas the frequency domain 
parameters included low frequency (LF) power (0.2-0.8 Hz), and high frequency (HF) 




Figure 2: The technique of the HRV recording. 
A) Recording in resting position. B) Recording in 70° head -up position. The images were 
taken from experiments of this study showing the rat inside the restrainer, the tail pulse 
plethysmography transducer placed at the base of rat tail, and showing how the data were 
recorded with the Power Lab data acquisition system. 
 
3.5 Heart isolation and perfusion technique  
The surgical procedure for heart isolation in rats was performed under general 
anaesthesia. The rats were anesthetized with sodium pentobarbitone (70 mg/kg 
body weight, i.p), following the injection with heparin (500 IU /kg body weight, i.p) to 
prevent thrombus formation. Once the depth of anaesthesia was recognized by the 
disappearance of the pedal withdrawal reflex, a thoracotomy was performed through 
an incision from the xiphoid sternum to the left and right costal margin. The anterior 
chest wall was deflected upward and the pericardium was opened. The heart then 
was excised at the level of the aorta and quickly transferred to a dish containing cold 
(4°C) Krebs-Henseleit (K-H) buffer solution that was prepared freshly and contained 
(in mmol/L) (NaCl 118.5, KCl 4.7, CaCl2 1.2, MgSO4 1.2, NaHCO3 25, KH2PO4 1.2 
and glucose 11, pH 7.4). The heart was quickly mounted on the Langendorff by 
aortic cannulation using a stainless-steel cannula and was tied with a 3-0 silk suture 
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(figure 3). The heart was perfused via retrograde perfusion with the Langendorff 
perfusion system using K-H buffer bubbled with 95% oxygen and 5% carbon dioxide. 
The perfusion pressure was kept on a constant pressure (74 mmHg). The 
temperature of K-H buffer solution was maintained at a constant temperature 
between 37-38°C by a heated water-jacketed system.  
 
3.5.1 Cardiovascular function assessments 
After aortic cannulation, the electrodes of the ECG (an apex to base electrogram that 
corresponds to the lead II on an ECG) were connected. The ECG electrodes 
included a positive electrode that was connected around the aorta; a negative 
electrode was connected to the apex of the heart and a ground electrode that was 
placed in the free part of the cannula (figure 3). The ECG electrodes were connected 
to the Power Lab data-acquisition system (AD Instruments, Australia) via an Animal 
Bio Amplifier (ML136, AD Instruments, Australia).  
For cardiac hemodynamic assessments, a deflated balloon was inserted into the LV 
through the left atrial appendage and the mitral valve. The balloon was connected to 
a pressure transducer (MLT0699, Australia). The pressure transducer was 
connected to the Power Lab data-acquisition system (AD Instruments, Australia) 
through a bridge amplifier (Bridge Amp ML221, AD Instruments, Australia).  
Once the Langendorff preparation was established, the balloon was inflated with 
water to get end diastolic pressure of 5-10 mmHg. Subsequently, the volume of the 
balloon was not changed, and the heart was perfused without further intervention. 
The hemodynamic parameters that were measured included the LV developed 
pressure (LVDP) (difference between systolic and diastolic pressure), HR, the 
maximal rate of left ventricular pressure increase (+dP/dt), and the maximal rate of 
LV pressure decline (-dP/dt). The rate-pressure-product (RPP) was calculated as 
LVDP × HR. In addition, the coronary flow rate was measured through the collection 
of the coronary effluent of the hearts over one minute.  
The exclusion criteria for all the experiments was as follows: hearts that lasted more 
than three minutes during aortic cannulation or hearts that failed to beat within sinus 
rhythm after mounting on the Langendorff perfusion system. 
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The data was captured and analysed with LabChart v8 software (AD Instruments, 
Australia). The ECG data was analysed with LabChart Pro ECG analysis v.2.4 
module software (AD Instruments, Australia). The haemodynamic data were 




Figure 3: The isolated rat heart mounted on the Langendorff perfusion system. 
The image shows the isolated rat heart mounted on the Langendorff perfusion system 
through aortic cannula. The ECG electrodes and the intraventricular balloon are connected.  
 
3.6 Histological studies  
Hearts used for histological studies were briefly perfused with K-H buffer solution for 
2 minutes to wash out the blood. The hearts were then blotted with tissue paper, 
weighed, and quickly sliced transversely from the apex into 4 slices (each about 
2-mm thickness). The heart slices were then fixed in 10% buffered formalin for 48 
hours to prevent degradation of tissue structure and keep integrity of cells and 
subcellular component. After fixation, the tissue was transferred into 70% alcohol for 
storage prior to processing.  
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Tissue processing was performed using an automated tissue processing system 
(Leica TP1020, Leica Biosystems, Germany), which allowed tissue processing with 
gentle agitation. The tissue processor system included dehydration in consecutive 
concentrations of alcohol (70%, 96%, 100%), clearing with xylene and paraffin wax 
impregnation with molten paraffin wax. Following tissue processing, the tissue was 
embedded in wax blocks using wax embedding system (WD-4, SA). The embedded 
tissues were sectioned with a rotary microtome (Leica RM2125RT, Leica 
Biosystems, Germany) into 4-μm thick sections. The tissue sections were mounted 
on glass slides and incubated in hot oven overnight to allow attachment of sections 
over slides. Tissue sections on slides were stained with Haematoxylin and Eosin 
(H&E) stain or with Masson’s trichrome stain. Detailed staining protocols are 
described in the Appendix 3.  
The slides were digitally scanned with the Olympus VS120 slide scanning system 
(Olympus VS120-L100 system, Germany). This system allowed for scanning of the 
whole slide automatically and produced high resolution images. The scanned slides 
were viewed with Olympus OlyVIA software (OlyVIA 2.8 Viewing software), and the 
images were captured as screenshots. 
The images were digitally analysed with ImageJ software (NHI, USA). Briefly, four 
images were captured from different areas within each heart and cell widths of 10-12 
cells per heart were measured to assess evidence of cardiac hypertrophy. Interstitial 
fibrosis was semi-quantified by assessing the degree of fibrosis using Masson’s 
trichrome staining as follows: (-); none, (+); mild, (++); moderate, (+++); severe, 
using guidelines as described by Buwa et al. (2016).  
 
3.7 Western blot analysis 
Western blot analysis was used to detect a marker of synaptic degradation 
synaptophysin, a presynaptic vesicle glycoprotein that is present in neuroendocrine 
cells and neurons. In addition, western blot was performed to assess a mitochondrial 




The right atrial tissue of the hearts used for western blot studies was separated, 
snap frozen in liquid nitrogen, and stored at -80°C until used for a western blot 
analysis. The frozen right atrial tissue was homogenised by sonication (Soniprep 
150, UK) for 20 seconds in Radioimmunoprecipitation (RIPA) lysis buffer containing 
50 mM Tris-Hcl (pH 8), 1% Triton x-100, 150 mM NaCl, 0.1% sodium dodecyl 
sulphate (SDS), 0.5% sodium deoxycholate with a protease and phosphatase 
cocktail inhibitor (Halt protease and phosphatase inhibitor, ThermoScientific, USA). 
The lysates were then centrifuged at 15000 relative centrifugal force for 30 minutes 
at 4°C (Labnet International, NJ07095, USA). The supernatant was collected and the 
protein concentration of supernatant was measured using the Pierce protein assay 
kit (Thermo Scientific, Rockford, USA.). The detailed western blot protocol is 
provided in Appendix 4. 
The loading samples were prepared with equal amounts of protein content of the 
lysate with Lammli dye (Bio-Rad, SA), RIPA buffer and diethyltritroil. The loading 
samples were then boiled for 4 minutes at 95°C, stored at -20o C and re-boiled for 4 
minutes at 95°C, then briefly centrifuged for 30 seconds on the desk mini-centrifuge 
(Toms, Laboratory Products) before use. The samples were then loaded and 
electrophoresed on 12% SDS-polyacrylamide gel using Mini-PROTEN Tetra Cell 
System (Bio-Rad, SA) at 150 voltage for 90 minutes.  
The protein was transferred from the gel to a Polyvinylidene fluoride (PVDF) transfer 
membrane (Immuno-Blot PVDF Membrane for Protein Blotting, Bio-Rad, SA), using 
a semi-dry transfer unit (Trans-Blot Turbo Transfer system, Bio-Rad, SA). The 
transfer process was confirmed by staining the PVDF membrane with ponceau stain. 
The membranes were then de-stained by washing with distilled water, and were then 
blocked with 5% non-fat milk in phosphate buffered saline with 0.1% Tween-20 
(PBS-T) for 1hour at room temperature. The membranes were incubated with 
primary antibodies (mouse monoclonal anti-synaptophysin, ab18008, Abcam, SA) or 
with Anti-ATP5A antibody (ATP5A: sc-136178 Santa Cruz Biotechnology, USA) 
against proteins of interest. Both primary antibodies were used at a dilution of 1:5000 
in 5% non-fat milk in PBS-T overnight at 4°C. The membranes were then washed 
with PBS-T and incubated with horseradish peroxidase (HRP), conjugated 
secondary antibody (Goat Anti-Mouse IgG HRP conjugate, #170-6516, Bio-Rad, 
27 
 
SA), at dilution of 1:10000 in 5% non-fat milk in PBS-T for 2 hours at room 
temperature. Next, the membranes were washed with PBS-T and then incubated 
with enhanced chemiluminescence (ECL) detection solution (Clarity Western ECL 
Substrate, Cat. #170-5060, Bio-Rad, SA) for 1-3 minutes. The membranes were then 
exposed to x-ray film (Agfar Healthcare, SA) in dark room. The membranes were 
immersed in a developer and then in a fixative solution for two minutes.  
The membranes were then washed with distilled water, stripped with 8% NaOH, and 
blocked with 5% non-fat milk in PBS-T for 1 hour. The membranes were incubated 
with housekeeping protein primary antibody (Monoclonal anti-alpha-tubulin antibody 
produced in mouse, T5168, Sigma-Aldrich, SA) at dilution of 1:3000 in 5% non-fat 
milk in PBS-T overnight at 4°C. The membranes were then washed with distilled 
water and incubated with horseradish peroxidase (HRP) conjugated secondary 
antibody (Goat Anti-Mouse IgG (H+L)-HRP conjugate, #170-6516, Bio-Rad, SA), at 
dilution of 1:10000 in 5% non-fat milk in PBS-T for 2 hours at room temperature. The 
membranes were then washed, incubated with ECL, and detected as above.  
The x-ray films were scanned and analysed using Image J software (Image J, NIH, 
USA). The density of each band was expressed as a percentage of the mean density 
of all the bands. The percentage of each band was then normalised to the 
percentage density of it is respective housekeeping protein bands. 
 
3.8 Plasma Mg2+ assay 
Blood used for Mg2+ assay was collected from the chest cavity immediately after 
excision of the heart and was centrifuged at 15000 relative centrifugal force 
(Beckman microfuge, USA) for 15 minutes to obtain plasma. The supernatant 
plasma was collected and then transferred into well labelled Eppendorf tubes and 
stored at -80°C for a later biochemical assay. An aliquot 0.5 ml of the plasma was 
used for measurement of the plasma Mg2+ concentration using automated 
photometric assay (Beckman AU, PathCare, SA). 
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3.9 Chemicals and reagents 
Sodium pentobarbitone was purchased from VetServ Laboratories (Cape Town, SA). 
All other chemicals were obtained from Sigma (Sigma-Aldrich, SA), unless stated 
otherwise. 
 
3.10 Statistical analysis  
In this study, data were presented as mean ± S.E.M. Data from multiple groups with 
normal distribution were compared using one-way analysis of variance (ANOVA) 
followed by appropriate Tukey’s post-hoc test. Successive measurements were 
compared using repeated measures ANOVA. Comparison of HRV data between the 
horizontal- and head-up tilt positions were analysed using paired t-test. A p-value of 
< 0.05 was regarded as statistically significant, n: represents the number of animals 
per group. The statistical analysis was performed by using Statistica 13 and Microcal 
Origin Lab programmes (Microcal Software, USA).  
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Chapter 4: Results 
 
4.1 General parameters 
4.1.1 Induction of diabetes and survival of the animals   
Thirteen out of 16 rats became diabetic with STZ treatment in the STZ group, and 12 
out of 13 rats became diabetic in the STZ+Mg treated group. Those rats that did not 
become diabetic were excluded from the study. In addition, the general animal 
welfare condition was stable for the period of the study and none of the diabetic or 
control animals died or were euthanized during the period of the study. 
 
4.1.2 The effect of Mg2+ treatment on blood glucose level in STZ-
induced diabetic rats 
Before STZ injection, there were no significant differences in the blood glucose level 
in all animal groups (figure 4. A). The non-diabetic control group was euglycemic 
(range of blood glucose 5-6 mmol/L) over the four weeks of study. STZ treatment 
induced a significant increase in the blood glucose level from first week onwards, 
which remained sustained over the four weeks (P < 0.001, STZ and STZ+Mg vs. 
control). The hyperglycaemia in STZ-treated animals was transiently lowered by 
Mg2+ treatment during week 1 and week 3 (P < 0.01, STZ+Mg vs. STZ). Mg2+ 
treatment alone did not alter blood glucose level (P > 0.05, Mg vs. control). 
 
4.1.3 The effect of Mg2+ treatment on the body weight changes in 
STZ- induced diabetes model                                                                       
The non-diabetic control animals showed normal body weight gain over the period of 
the study (figure 4.B). The STZ-treated animals showed loss of body weight from the 
first week of the study (P < 0.01, STZ and STZ+Mg vs. control). Mg2+ treatment in 
STZ-treated animals had no significant effect on the loss of body weight (P > 0.05, 
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STZ+Mg vs. STZ). Mg2+ treatment alone did not change the trend of body weight (P 
> 0.05, Mg vs. control). 
 
 
Figure 4: Weekly measurement of blood glucose and body weight for the different treatment 
groups. A) Weekly blood glucose level for the various treatment groups. B) Weekly body 
weight changes for all treatment groups. *P < 0.05 vs. control; **P < 0.01 vs. control, ***P < 





































































4.1.4 The effect of Mg2+ treatment on the plasma Mg2+ concentration 
in STZ - induced diabetic rats 
To find out if the effects of treatment were related to changes in plasma Mg2+ level, 
the plasma concentration of Mg2+ at four weeks were analysed. There were no 
significant differences in the concentration of the plasma Mg2+ between the different 
groups (P > 0.05, STZ and STZ+Mg vs. control, figure 5). Mg2+ treatment alone had 
no significant effect on plasma Mg2+ concentration (P > 0.05, Mg vs. control). 
 
Figure 5: Plasma Mg2+ Concentration for the different treatment groups. 




































4.2 Magnesium treatment improved heart rate variability in 
diabetes 
4.2.1 The Time Domain parameters of HRV  
STZ treatment significantly decreased RMSSD compared to control (P < 0.05, STZ 
vs. control), and this STZ effect was prevented by Mg2+ treatment (P < 0.05, STZ+Mg 
vs. STZ) (figure 6. A). Mg2+ treatment alone had no significant effect on RMSSD (P > 
0.05, Mg vs. control). 
The non-diabetic control animals had a normal resting HR of about 460 bpm (figure 
6. B). STZ significantly reduced HR compared to control group (P < 0.05, STZ vs. 
control), and this STZ effect was reversed by Mg2+ treatment (P < 0.05, STZ+Mg vs. 
STZ). Mg2+ treatment alone had no significant effect on HR compared to control (P > 





Figure 6: The effects of Mg2+ and STZ treatment on the time domain parameter of HRV and 
HR for the various treatment groups. 
A) RMSSD parameter for different treatment groups. B) HR data for various treatment 

















































4.2.2 The Frequency Domain parameter of HRV  
STZ treatment significantly increased LF/HF ratio compared to control group (P < 
0.01, STZ vs. control, figure 7). This effect of STZ on LF/HF ratio was prevented by 
Mg2+ treatment (P < 0.01, STZ+Mg vs. STZ). Mg2+ treatment alone had no significant 
effect on LF/HF ratio compared to control (P > 0.05, Mg vs. control). 
    
Figure 7: The effects of Mg2+ and STZ treatment on frequency domain parameter for the 
different treatment groups. 
**P < 0.01 vs. control, ##P < 0.01, and ###P < 0.001 vs. STZ, n = 7-9. 
 
4.2.3 The orthostatic stress response of heart rate  
The orthostatic stress test was performed to explore the changes of HR from resting 
horizontal position to 70° head-up position. The non-diabetic control animals showed 
normal response orthostatic stress induced tachycardia in the tilt position compared 
to horizontal resting position (P < 0.05, control 70° position vs. horizontal position, 
figure 8). The STZ-treated animals showed impaired HR response to orthostatic 
stress compared to resting position (P > 0.05, STZ 70° position vs. horizontal 























position vs. horizontal position). The Mg2+ treatment alone showed normal response 





Figure 8: The effects of STZ and Mg2+ treatment on the response of HR to orthostatic stress 
test. 
*P < 0.05, ***P < 0.001: head-up position vs. horizontal position. n.s: not significant, n = 7-9. 
   
4.3 The effects of Mg2+ and STZ treatment on cardiac 
synaptophysin protein expression 
To evaluate the mechanism through which the Mg2+ effects on autonomic 
dysfunction may occur, western blot analysis of autonomic synaptic innervation was 
performed. Representative image of western blot analysis in Figure 9 shows the 
bands of proteins in different treatment groups for synaptophysin and a 
housekeeping protein (alpha tubulin). Generally, there was an absence of 
synaptophysin protein bands in three among of four western blot analysis in STZ 






















 70° Head-up position
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Qualitatively, western blot analysis showed a decrease in the expression of 
synaptophysin protein in STZ-treated only group (STZ) compared to control groups. 
In addition, qualitatively Mg2+ treatment improved synaptophysin protein expression 
in STZ group (STZ+Mg). Mg2+ treatment alone showed similar pattern of 
synaptophysin expression similar to the control group. 
 
Figure 9: Representative immunoblot bands of synaptophysin and alpha tubulin proteins for 
the various treatment groups. n= 3-4. 
 
4.4 The effects of Mg2+ and STZ treatment on cardiac 
mitochondrial ATP5A expression 
To explore the role of mitochondrial oxidative stress in cardiac autonomic 
dysfunction, western blot analysis was performed for mitochondrial ATP synthase 
(ATP5A) expression in the heart. Representative image of western blot analysis 
(figure 10) showed the bands of ATP5A and alpha tubulin proteins for all treatment 
groups. Qualitatively, western blot analysis showed the expression of mitochondrial 




Figure 10: Representative immunoblot bands for ATP5A and alpha tubulin proteins for the 
different treatment groups. n= 3-4. 
 
4.5 The effects of Mg2+ treatment on ECG changes in STZ-
induced diabetic model 
The representative traces of ECG waveform are shown in figure 11, and the changes 
in ECG parameters for various treatment groups are summarized in table 1. The STZ 
treatment significantly decreased heart rate (P < 0.01, STZ vs. control). Mg2+ 
treatment did not affect STZ-induced bradycardia (P > 0.05, STZ+Mg vs. STZ or 
control), and had no significant effect on RR interval (P > 0.05, STZ+Mg vs. STZ or 
control). Mg2+ treatment alone had no significant effects on HR (P > 0.05, Mg vs. 
control), or RR interval (P > 0.05, Mg vs. control). There were no significant 
differences of R wave amplitude, S wave amplitude, T wave amplitude, QRS interval, 




Figure 11: The effects of Mg2+ and STZ treatment on ECG waveforms. 







Table 1: Summery data of ECG characteristics for various treatment groups. 
 
4.6 The effects of Mg2+ treatment on haemodynamic 
parameters in STZ-induced diabetic rat model 
 
4.6.1 Mg2+ treatment improved hemodynamic function  
Generally, the non-diabetic control animals had LVDP of about 100 mmHg. The 
STZ-treated animals showed a significant decreased LVDP compared to control 
animals (P < 0.05, STZ vs. control, figure 12 A). Mg2+ treatment significantly 
prevented STZ-induced decreased LVDP (P < 0.05, STZ+Mg vs. STZ). Mg2+ 
treatment alone had no significant effect on LVDP (P > 0.05, Mg vs. control). 
The STZ-treated animals also showed a reduction in the maximal rate of LV 
pressure increase (+dP/dt) compared to the control animals (P < 0.01, STZ vs. 
control, figure 12 B). This STZ effect on +dP/dt reversed by Mg2+ treatment (P < 
0.05, STZ+Mg vs. STZ). The STZ-treated animals showed a decrease in the 
maximal rate of LV pressure decline (-dP/dt) compared to the control animals (P < 
0.05, STZ vs. control, figure 12 C), which was not prevented by Mg2+ treatment (P > 
0.05, STZ+Mg vs. STZ or control). Mg2+ treatment alone had no significant effects on 
+dP/dt and -dP/dt (P > 0.05, Mg vs. control). There were no significant differences 
ECG parameter Control STZ STZ+Mg Mg 
Heart rate (bpm) 233 ± 8 178 ± 14* 209 ± 11 234 ± 13 
RR interval (s) 0.27 ± 0.01 0.34 ± 0.03* 0.29 ± 0.02 0.26 ± 0.01 
R amplitude (mV) 5.2 ± 0.7 5.6 ± 1.3 6.2 ± 1.1 6.2 ± 0.8 
S amplitude (mV) 1.75 ± 0.27 2.1 ± 0.63 2.35 ± 0.73 0.40 ± 1.38 
T amplitude (mV) 2.12 ± 0.53 2.56 ± 0.67 2.73 ± 0.95 1.76 ± 0.46 
QRS interval (s) 0.020 ± 0.003 0.024 ± 0.002 0.026 ± 0.006 0.024 ± 0.003 
QT interval (s) 0.062 ± 0.002 0.079 ± 0.009* 0.065 ± 0.005 0.064 ± 0.006 
QTc (s) 0.124 ± 0.006  0.137 ± 0.016  0.119 ± 0.007 0.121 ± 0.009 
  
QTc was calculated with Bazett, s formula. Data are presented as mean ± SEM, *P < 0.05 vs. 
control. n= 7 -11. 
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between the different treatment groups in RPP, systolic duration, and diastolic 
duration (figure 12 D-F). 
 
 
Figure 12: The effects of STZ and Mg2+ treatment on haemodynamic parameters for various 
treatment groups. The haemodynamic parameters includes A: left ventricular developed 
pressure (LVDP), B: maximal rate of LV pressure increase (+dp/dt), C: maximal rate of LV 
pressure decline (- dp/dt), D: rate pressure product, E: systolic duration and F: diastolic 
duration. *P < 0.05 vs. control, **P < 0.01 vs. control, #P < 0.05 vs. STZ, and ##P < 0.01 vs. 





























































































































4.6.2 The effects of STZ and Mg2+ treatment on coronary flow rate 
To further explore the mechanisms underlying the improvement of contractile 
function by Mg2+ in diabetes, the changes in the coronary flow rate were analysed. 
There were no significant differences between different treatment groups in coronary 
flow rate (figure 13) (P > 0.05, STZ and STZ +Mg vs. control or Mg). 
 
Figure 13: The effects of STZ and Mg2+ treatment on coronary flow rate for different 
treatment groups. 
The coronary flow rate was normalized to heart weight. n.s: not significant, n= 7-9. 
 
4.7 The effects of STZ and Mg2+ treatment on cardiac 
structure 
4.7.1 Changes in heart weight 
The hearts were weighed to assess if there were changes in gross cardiac 






































day 28 of the study) (HW/BW ratio). There were no significant differences in HW/BW 
ratio among the different groups (P > 0.05, STZ and STZ+Mg vs. control or Mg) 
(figure 14).  
 
Figure 14: The effects of STZ and Mg2+ treatment on heart weight/ body weight ratio. 
n.s: not significant, n = 7-9. 
 
4.7.2 Analysis of cardiac cell size 
Cardiac histological features were also analysed in order to infer cardiac function 
improvements in diabetes. Representative images of H&E stained ventricular tissue 
for various treatment groups (figure 15 A). The images showed regularly arranged 
cardiac myofibers and uniform sizes of spaces between cells that are consistent with 
lack of interstitial infiltrations. Cardiomyocytes widths were measured as an index of 
cardiomyocyte hypertrophy. There were no significant differences in cardiomyocytes 
widths among the groups (P > 0.05, for STZ and STZ+Mg vs. control or Mg) (figure 























Figure 15: The effects of STZ and Mg2+ treatment on histology of cardiomyocyte. 
A) Representative images of histological staining (H&E) of ventricular tissue, scale bar in 
lower right corner represent 100 μm. B) Cardiac cell width analysis for various groups. n.s: 
not significant, n= 5-6. 
  
4.7.3 Analysis of ventricular tissue fibrosis 
Examples of images of Masson’s trichrome stained ventricular tissue showed no 






















of Masson’s trichrome stained perivascular tissue (figure 17) also showed no 
detectable perivascular fibrosis among the different treatment groups. 
 
 






Figure 16: The effects of Mg2+ and STZ treatment on the extent of interstitial fibrosis for 
different treatment groups. 
Representative images of Masson’s trichrome stained ventricular tissue showed: A) 
interstitial area. The labelled scale bar in the bottom represents 50 μm. B) Arbitrary score of 













Figure 17: The effects of STZ and Mg2+ treatment on the extent of perivascular fibrosis for 
the various treatment groups. 
Representative images of Masson’s trichrome stained ventricular tissue showed: A) 
perivascular area. The labelled scale bar in the bottom represents 50 μm. B) Arbitrary score 






Chapter 5: Discussion 
 
In the current study, we have shown that the chronic DM is associated with 
cardiovascular complications that include cardiac autonomic dysfunction and 
impairment in cardiac hemodynamic function. Daily Mg2+ treatment in chronic 
diabetes attenuated cardiac ventricular dysfunction without affecting coronary flow 
rate or ECG parameters. Mg2+ administration also improved HRV impairment in 
chronic DM, without evidence of mitochondrial oxidative marker of ATP5A. However, 
neither the blood glucose level nor plasma Mg2+ concentration or cardiac 
morphological structures were affected by Mg2+ treatment.  
Diabetic animals showed hyperglycaemia throughout the four weeks. Treatment with 
Mg2+ did not affect the induction rate of diabetes or the hyperglycaemia. This result 
was supported by previous studies, which showed that the administration of Mg2+ 
does not improve hyperglycaemia or the diabetic induction in both chronic diabetic 
animal model (Hans, Chaudhary, and Bansal 2003, Rondon et al. 2010) and in 
diabetic patients (de Valk et al. 1998). In contrast to our results, some studies 
showed that the Mg2+ treatment improved hyperglycaemia in diabetic model 
(Hasanein et al. 2006, Parvizi et al. 2014, Patel, Raghunathan, and Porwal 2014, 
Soltani et al. 2005). Soltani et al. (2005) showed histological evidence that Mg2+ 
administration has a protective effect on the pancreatic β-cell from the cell 
destruction induced by STZ. 
In the present study, DM-induced decreased RMSSD, which is indicative of 
parasympathetic activity according to Task Force of The European Society of 
Cardiology and The North American Society of Pacing and Electrophysiology (1996). 
DM also induced increased LF/HF ratio, which is a marker of enhanced sympathetic 
activity. Therefore, the present study based on these HRV parameters showed that 
there was an impairment of both parasympathetic and sympathetic activity in chronic 
diabetes. These results are consistent with previous studies where there was an 
impairment of both sympathetic and parasympathetic cardiac autonomic function in 
chronic STZ-induced diabetic rat model (Li et al. 2015, Sanyal et al. 2012). Sanyal et 
al. (2012) showed that the parasympathetic autonomic impairment occurred in early 
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onset of DM, while the sympathetic autonomic disturbances happened much later 
after the onset of DM. 
In the current study, DM also impaired orthostatic stress-induced tachycardia. The 
orthostatic response is indicative of the integrity of baroreceptor reflex (Cowley, 
Liard, and Guyton 1973, Steinback et al. 2005). The impairment of baroreceptor 
reflex has been observed in short term STZ-induced diabetes (Amoni et al. 2016, 
Dall'Ago et al. 2002, Maeda et al. 1995). Therefore, taken together, the impairment in 
HRV parameters and orthostatic stress response in the present study indicate that 
the DM-induced cardiac autonomic dysfunction. 
In the present study, MgSO4 administration improved diabetes-induced decreased 
RMSSD, increased LF/HF ratio, and impaired orthostatic stress response in chronic 
diabetic model. Therefore, the findings of this study suggested that the Mg2+ 
administration could prevent diabetes induced HRV impairment in chronic diabetes. 
Several studies have also reported that the Mg2+ treatment has a beneficial effect in 
neuronal studies. For instance, Sameshima, Ota, and Ikenoue (1999) showed that 
the Mg2+ treatment protects the brain against ischemic injury in neonatal rats. In 
addition, Begon et al.(2000) demonstrated that the Mg2+ treatment in STZ-induced 
diabetic rats improves neuropathic pain. In cardiovascular conditions, Mg2+ 
administration improved HRV impairment in non-diabetic patients with systolic heart 
failure (Almoznino-Sarafian et al. 2009). Furthermore, in our laboratory study by 
Amoni et al. (2016) showed that the Mg2+ treatment improved HRV disturbances in 
acute STZ-induced diabetes in rats. Therefore, the findings of the current study are 
novel in chronic diabetes and suggest that the effect of Mg2+ is long lasting. 
Based on the observation of synaptic innervation of the present study, the possible 
underlying mechanism of our results is that the Mg2+ treatment may involve the 
preservation of synaptophysin innervation in the diabetic animals. This mechanism 
for Mg2+ effect is consistent with a study by Sanyal et al. (2012) where there was 
degradation in the synaptic autonomic innervation in chronic STZ-induced diabetic 
rat. Their findings were observed through ultrastructural studies of sinoatrial region. 
Additionally, Yang and Chon (2011) demonstrated that there was a reduction of 
nerve density (as was evidenced by the decreased expression of synaptophysin) in 
spontaneously diabetic mice. 
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Furthermore, Mg2+ effects were unrelated to its effect on the expression of 
mitochondrial ATP synthase in the right atrium, since there was no apparent change 
in the expression of the protein. However, this finding does not exclude oxidative 
stress as an underlying mechanism for cardiac autonomic dysfunction because the 
other important markers of oxidative stress in DM such as malondialdehyde and 
superoxide dismutase were not evaluated in this study. These oxidative stress 
parameters have been implicated in STZ-induced diabetic rats, and were prevented 
by Mg2+ treatment (Patel, Raghunathan, and Porwal 2014). 
The diabetic animals in this study also showed baseline bradycardia, which is 
inconsistent with impaired parasympathetic activity suggested by the HRV findings. 
Similar findings were observed in previous studies where diabetes-induced resting 
bradycardia in animal disease models (Borges et al. 2006, Dowell, Atkins, and Love 
1986, Jackson and Carrier 1983). In addition, in our study bradycardia was also seen 
in ex-vivo Langendorff perfused experiments, and this finding is also consistent with 
previous studies (Howarth et al. 2007, Howarth and Qureshi 2006). Senges et al. 
(1980) have suggested that the bradycardia in diabetic model is due to derangement 
in an intrinsic electrophysiological activity of sinoatrial node. 
Our study also showed decreased LVDP, RPP, +dP/dt, and -dP/dt in diabetes, all of 
which suggest that there was impaired LV contractile function in chronic diabetes. 
The +dP/dt has been used generally as an index of cardiac contractility, while the -
dP/dt is an indicative of diastolic relaxation (Kass et al. 1987, Schmidt and Hoppe 
1978). The RPP is a reliable predictor of myocardial oxygen demand (Forjaz et al. 
1998, May and Nagle 1984). The results of this study are consistent with those 
reported in previous studies (Litwin et al. 1990, Radovits et al. 2009) where there 
was a decrease in the LV systolic pressure, +dP/dt and -dP/dt. Litwin et al. (1990) 
found that the cardiac dysfunction could be reversed by insulin administration. In 
addition, impaired cardiac performance has been documented in isolated cardiac 
cells (Ren and Bode 2000). Moreover, several studies showed that there were 
disturbances in cardiac contractility in diabetic disease models (Hamblin et al. 2007, 
Trost et al. 2002). In contrast to the findings in our study and from several other 
studies, Connelly et al. (2007) have reported that there was unaltered cardiac 
function in chronic STZ-induced diabetic rats. However, their diabetic rats were 
treated with insulin, which could have masked the incidence of diabetic cardiac 
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dysfunction. Insulin treatment also increases myocardium Ca2+ uptake, therefore it is 
an important factor for cardiac function (Gotzsche 1985). 
Mg2+ administration in this study prevented chronic diabetes-induced changes in 
LVDP and +dP/dt, but did not affect -dP/dt or RPP. Our findings are in agreement 
with those of previous studies that reported that the Mg2+ has a cardioprotective 
effect in DM. In our laboratory, Amoni et al. (2016) demonstrated a similar effect of 
Mg2+ in preventing ventricular dysfunction in acute STZ-induced diabetic rat. Another 
study by Amoni et al. (2017) also demonstrated cardioprotective effects of Mg2+ in 
non-diabetic cardiac hypertrophic rat model. In addition, the study by Patel, 
Raghunathan, and Porwal (2014) reported that the Mg2+ valproate supplementation 
improved hemodynamic dysfunction in chronic STZ-induced diabetic rats. The 
beneficial effect of Mg2+ valproate was proposed to be underlined by the attenuation 
of oxidative stress in DM. Nevertheless, it is not clear whether this effect is related to 
Mg2+ ion or to the valproate component. Furthermore, in non-diabetic conditions Mg2+ 
administration prevented ventricular dysfunction induced by ritonavir through 
improvement of oxidative stress and hyperlipidaemia disorders in the rat model (Mak 
et al. 2013). Therefore, the result of the current study suggests that Mg2+ treatment 
could improve cardiac contractile dysfunction in chronic diabetes.  
The mechanisms underlying the improvements in ventricular performance by Mg2+ in 
our study are not clear. There is a correlation between Mg2+ and coronary artery 
function where Mg2+ stimulates prostaglandin release (Nadler, Goodson, and Rude 
1987), which increases coronary flow rate and decreases coronary artery resistance 
(Bergman et al. 1981). However, the beneficial effects of Mg2+ administration in the 
current study were unrelated to the changes in the coronary perfusion rate. 
Furthermore, in the current study, there were no changes in ECG parameters, 
suggesting that the underlying mechanisms by which Mg2+ improved cardiac 
dysfunction in chronic diabetic model was unrelated to its effect on the cardiac 
electrical remodelling. It is however well known that the Mg2+ has an anti-arrhythmic 
effect (James 2009, Miyoshi et al. 2000). In addition, Mg2+ is also an essential factor 
for sodium-potassium ATPase, which is the main enzymatic activity for intracellular 
potassium transport during action potential period (Abbott and Rude 1993, Parikka et 
al. 1999).  
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The current study showed no morphological changes in the diabetic heart. The gross 
heart weight was unaltered, and the histological studies showed no evidence of 
structural changes in the cardiomyocyte cell size or interstitial fibrosis. These 
findings are in agreement with previous studies. Mihm et al. (2001) documented that 
there were diastolic and systolic dysfunction occurred in the time course of chronic 
DM, but without histological evidence of cardiac hypertrophy or fibrosis. In addition, 
Litwin et al. (1990) showed that there was a cardiac dysfunction without histological 
alteration in the myocardium, and there was no evidence of interstitial fibrosis in 
chronic STZ-induced diabetic rats. In contrast, previous studies in chronic STZ-
induced diabetic rats showed that there was a cardiac dysfunction with histological 
evidence of cardiomyocyte hypertrophy and fibrosis (Matyas et al. 2015, Radovits et 
al. 2015). In addition, the study by Akula et al. (2003) showed that there was LV 
diastolic and sytolic dysfunction based on echocardiography performed at 12 weeks 
of STZ-induced diabetic rats . However, the lack of histological alterations in our 
study supports the concept that the nature of diabetic ventricular dysfunction is 
functional rather than structural.  
Although hypomagnesemia is a common metabolic disorder in DM (Chetan P. Hans 
2002, Rude 1992), our study showed no changes in plasma Mg2+ concentration. 
Hypomagnesemia has been reported in long term uncontrolled DM (Nagase 1996, 
Sjogren, Floren, and Nilsson 1986). However, the underlying mechanism of 
hypomagnesemia in DM is incompletely understood. Osmotic diuresis has reported 
for a part of Mg2+ loss in DM (de Valk 1999, Djurhuus et al. 2001). Unaffected 
plasma Mg2+ level in our study did not rule out the occurrence of hypomagnesemia in 
our diabetic model, because we did not evaluate Mg2+ concentration at tissue level 
and even at the intracellular compartment. 
 
Limitation of the study and future studies 
One limitation of this study is that, although the STZ-induced chronic diabetic 
complications are known to be similar to those in humans (Wei et al. 2003), there is 
debate regarding verification of the beneficial effects of Mg2+ in clinical trials. Another 
limitation is to do with the use of Langendorff perfusion experiments and this set up 
isolates hearts from the whole body and disturbs the normal hormonal and neuronal 
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cardiac innervation. Furthermore, the underlining mechanisms of the beneficial 
effects of Mg2+ in this study need further clarification. 
Further investigations are required to evaluate the precise mechanisms of Mg2+ 
effects. Although our western blot study showed a decrease in the synaptophysin 
cardiac innervation a further study of other related markers such as hyperpolarization 
-activated channel (HCN1) expressed in the sinoatrial node, and postsynaptic nerve 
innervation marker such as PSD95. Furthermore, further metabolic studies to 
evaluate the involvement of oxidative stress and AGEs will provide a good 
clarification of the role of Mg2+ in diabetic cardiovascular complications.  
 
Conclusion 
The results of this study showed that Mg2+ administration prevented diabetes-
induced cardiac autonomic dysfunction and impairment of cardiac function in chronic 
DM. However, the overall effects of Mg2+ were independent on the hyperglycaemia 
or plasma Mg2+ level. The improvement in autonomic dysfunction by Mg2+ in chronic 
diabetes could have possibly occurred through the preservation of the cardiac 
autonomic synaptic integrity. The mechanism through which Mg2+ improved 
ventricular dysfunction seemed to be unrelated to the effect of Mg2+ on gross cardiac 
morphological and histological structural changes, electrical remodeling, or coronary 
perfusion. The clinical implications of our findings are that Mg2+ treatment may have 
long-lasting beneficial effects on the cardiac autonomic impairment and ventricular 
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 Appendix 2: STZ preparation 
 
1- Preparation of the STZ vehicle (citrate buffer) 
A) 0.1M citric acid: weigh 0.210 g of citric acid monohydrate and dissolve in 10 ml of 
distilled water. 
B) 0.1M sodium citrate: weigh 0.294 g of sodium citrate tribasic dehydrate and 
dissolve in 10 ml of distilled water. 
Prepare citrate buffer (10 ml) by mixing 4.7 ml of 0.1M citric acid with 5.3 ml 0.1M 
sodium citrate. Check the pH and adjust it to 4.5 where is not there. 
  
2- STZ preparation and injection 
Calculate the amount of STZ required for each rat (50 mg/kg body weight). STZ 
powder placed in foil covered Eppendorf tube (STZ is a light sensitive). Mix 1 ml of 
citrate buffer with 50 mg STZ and keep in ice after preparation. 
Using 1ml syringe and 24-G needle inject the STZ solution intraperitoneally (within 
15 minutes after STZ preparation) per the weight of each rat. For example, rat 
weighting 250 g, it needs 12.5 mg STZ therefore inject with 0.25 ml of STZ. The 
control rats were injected with citrate buffer in equal amount of the STZ. The rats 










Appendix 3: Histological protocol 
 
1: Tissue preparation and fixation 
After heart isolation, the heart washed shortly about 2 minutes with Krebs solution to 
washout the blood, then sliced transversely into four slices about 2 mm. The heart 
slices then fixed in 10% phosphate buffered formalin for 48 hours then transferred 
into new container containing 70% alcohol for storage until all the samples collected 
to process together. 
2: Tissue processing 
The fixed heart tissues were processed using an automated tissue processing 
system (Leica TP1020, Leica Biosystems, Germany). The heart slices placed in a 
plastic cassata, labelled then placed in the system, and the program P2 among 
systems program was used for tissue processing. The automated processing system 
works for 22 hours for processing the tissues and includes the following stages: 
A: Dehydration: the tissues were dehydrated with serial increasing concentration of 
alcohol as follow: 
70% alcohol: 2 x 1hour                         96% alcohol: 2 x 1hour 
Absolute alcohol: 2 x 1hour  
B: Clearing with xylene: 2 x 1hour 
C: Impregnation with melted paraffin wax: 2 x 1hour. 
3: Tissue embedding 
 Immediately after tissue processing, the tissue slices placed in metal block and 
embedded with melted wax using a wax melting system (WD-4, SA). The block was 






4: Sectioning  
The tissue slices in wax block were sectioned into 4-μm thickness sections with a 
rotatory microtome (Leica RM2125RT, Leica Biosystems, Germany). The wax block 
was first firmly clamped in the block holder, then align the wax block with knife, 
sectioning was done with turning of hand wheel. The section was lifted with un-
toothed forceps and transferred into dish containing 30% alcohol, after that the 
section transferred into distilled water bath at 42°C (Leica HI 1210, SA). Finally, the 
sections were lifted in slide, and the slides allowed to dry then putted in the oven to 




A- Haematoxylin and eosin (H&E) staining technique 
1- De-wax in xylene: 2 x 5 minutes. 
2- Hydration: in serial decreasing concentration of alcohol 
Absolute alcohol: 3 x 2 minutes.         96% alcohol: 2 x 2 minutes.  
70% alcohol: 1 x 2 minutes.  
3- Rinse in running tape water: 1 x 1 minute. 
4- Stain with haematoxylin: 5 minutes. 
5- Rinse in running tap water: 1 minute. 
6- Mordant in Scott’s tap water: 1 minute. 
7- Rinse in running tap water: 1 minute. 
8- Stain with eosin: 4 minutes.  
9- Rinse shortly in running tap water: < 10 seconds. 
10- Dehydration: in a serial increasing concentration of alcohol (briefly < 5seconds 
with agitation).  
70% alcohol: 2 x < 5 seconds.                96%: 2 x < 5 seconds.  
Absolute alcohol: 2 x < 5 seconds.  
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11- Clearing in xylene: 2 x < 10 seconds and the slides lifted in second xylene until 
ready to be mounted.  
12-Section mounting: with dibutyl phthalate –DPX, and place the coverslip over the 
tissue and the excess DPX removed carefully.  
13- Leave the slides to dry at room temperature. 
Expected results: blue: nucleus, pink: cytoplasm, erythrocyte, muscle, and collagen 
fibres. 
 
B- Masson’s trichrome staining technique 
1- De-wax in xylene:  2 x 5 minutes. 
2- Hydration: in serial decreasing concentration of alcohol. 
Absolute alcohol: 3 x 2 minutes.  96% alcohol: 2 x 2 minutes.  
70%: 1 x 2 minutes.  
3- Rinse in distilled water: 1 x 1 minute. 
4- Mordant the slides in Bouin’s Solution overnight at room temperature.  
5- Rinse the slides in running tap water to remove the yellow colour then with 
distilled water.  
6- Stain in Celestine blue: 5 minutes then rinse briefly with running tap water. 
7- Stain with haematoxylin: 5 minutes. 
8- Mordant in Scott’s tap water: 1 minute. 
9- Rinse in running tap water: 1 minute. 
10- Stain with Biebrich Scarlet- acid fuchsin solution: 5 minutes. 
11- Rinse in distilled water: 1 minute. 
12- Decolourize with 2.5% phosphotungstic acid-phosphomolybdic acid solution: 5 
minutes. 
13- Stain with aniline blue solution: 5 minutes. 
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14- Rinse in distilled water: 1 minute. 
15- Enhance differentiation in 1% acetic acid solution: 3 minutes. 
16- Rinse in distilled water: 1 minute. 
17- Dehydration, clearing, and mounting steps same as that for H&E staining. 





Appendix 4: Western blot protocol 
 
1- Preparation of buffers               2-Sample preparation  
3- Protein Quantification              4- Gel preparation and electrophoresis 
5-Transfere process                     6- Blocking of the membrane and antibody probing         
7- Enhanced Chemiluminescence (ECL) detection       
8- Stripling and re-probing                9- Scanning and analysis 
 
1- Preparation of buffers 
The following buffers are required for western blot analysis: 
A- Radioimmunoprecipitation assay buffer (RIPA buffer): recipe for 50 ml include: 
NaCl (5 molar) 1.5 ml, Triton X -100 (100%) 500 ul, SDS (10%) 500 ul, Tris (1molar, 
Ph 7.5), Deoxycholate sodium 0.5 g and distilled water 46.5 ml. 
B- Phosphate Buffered Saline-Tween (PBS-T×1): 8 g NaCl, 0.2 g KCl, 1.44 g 
Na2HPO4, 0.24 g KH2PO4, 2 ml Tween 20 and up to1000 ml distilled water, stir for 20 
minutes and adjust the pH to 7.4. 
C- Running (tank) buffer: using a Bio-Rad buffer (10× Tris/Glycine/SDS TGS Buffer, 
Bio-Rad SA). Mix 100 ml of TGS with 900 ml of distilled water. 
D- Transfer buffer: using Bio-Rad buffer (Trans -Blot Turbo ×5 Transfer buffer, Bio-
Rad SA). Mix 200 ml of 5× transfer buffer with 600 ml of distilled water and 200 ml of 
ethanol. 
E- Stripling buffer: 8 g NaOH in 1liter distilled water. 
 
2- Sample preparation 
A- Retrieve the frozen right atrial tissues from -80°C freezers. The tissue weighed 
and placed in new labelled Eppendorf tube and calculate the amount of RIPA 
extraction buffer (weigh of tissue in gram ×19), this gives the volume of RIPA needed 
86 
 
to add to tissue before homogenisation. Add protease and phosphatase inhibitor 
cocktail (Halt protease &phosphatase inhibitor, ThermoScientific, USA) 2 ul of 
cocktail inhibitor per 1 ml of RIPA buffer. 
B- Tissue homogenisation by sonication (Soniprep 150, UK). The Eppendorf tube 
with tissue and RIPA inside are placed in fetched place in the sonicator and allow the 
Soniprep probe just touch the tissue inside the Eppendorf and sonicate at 180 watts 
for 20 seconds until all tissue get homogenised in the buffer. 
C- Centrifuge the samples in a centrifuge (Labnet International, NJ07095 USA), at 
15 000 relative centrifugal force at 4°C for 30 minutes then transfer the supernatant 
into well labelled Eppendorf tube and make aliquot of 20 ul for protein assay and 
store at -80°C. 
 
3- Protein quantification 
BCA protein assay using the Pierce protein assay kit (Thermo Scientific, Rockford, 
USA). 
A- Preparation of diluted bovine serum Albumin (BSA) standards using RIPA buffer 
as diluent and standard Bovine serum solution as follows: 
Vial                                      volume of diluent (ul)                  volume of BSA(ul) 
A                                                 0                                                 300 of stock 
B                                               125                                               375 of stock 
C                                                325                                              325 of stock 
D                                               175                                               175 of vial B dilution  
E                                               325                                               325 of vial C dilution  
F                                                325                                              325 of vial E dilution  
G                                               325                                               325 of vial F dilution 
H                                               400                                               100 of vial G dilution 




B- Preparation of BCA working reagent 
To calculate the amount of working reagent required use the following formula: 
Number of standard used + number of samples ×2 (for duplicate) +1 for pipetting 
error ×200 (amount required per well). To prepare WR mix 50 parts of reagent A and 
one part of reagent B giving a clear green solution. 
C- For a microplate procedure using a flat bottom 96 wells plate, pipette 25 ul of 
standards in duplicate, 10 ul of samples in duplicate. Add 50 ul of RIPA buffer to the 
samples and 200 ul of working reagent to both standards and samples. Shake the 
microplate briefly and cover with parafilm and incubate in the oven at 37°C for 30 
minutes. 
D- Measure the absorbance in plate reader (RT-2100C, Microplate Reader, 
Germany) at 562 nm. Create a standard curve and calculate the volume of protein 
sample required and other recipe, which include RIPA buffer, Lammli dye (Bio-Rad, 







4- Gel preparation and electrophoresis 
Prepare 12% SDS -PAGE gels using ready prepared solution for gel casting (TGX  
Fast Cast  Acrylamide Kit,10% Cat. #161-0173, Bio-Rad SA). Prepare resolving and 
stacking gel (note to add 10% Ammonium persulphate (ASP) and 
Tetramethylethylendiamine (TEMED) just before use. Align glass plates and fix them 
well in the casting stand and load the resolving gel until about 1cm below the green 
line of the casting stand. Add layer of 20% SDS or 100% isopropanol to allow 
polymerization without oxygen for 10 minutes then remove the layer of SDS. Load 
the stacking gel and insert the comb to form wells. Allow the gel to set for 30 minutes 
in room temperature. The hand casted gel can be stored at 4°C for later use. 
The prepared samples denatured by boiling at 95°C for 4 minutes then stored in 
aliquot at -20°C. Before loading the samples were re-boiled at 95°C for 5 minutes, 
then vortex and centrifuge shortly. Place the gel into electrophoresis chamber and fill 
with tank buffer and remove the comb carefully from gel and wash the wells with tank 
buffer. Load 20 ug of samples and molecular weight marker into wells and record the 
order of loading. Using Mini-PROTEN Tetra Cell System (Bio-Rad, SA), Connect the 
electrodes red to red and black to black and switch on the power and run consonant 
voltage at 150 voltage for 90 minutes. 
 
5- Transfer process 
Transfer protein from gel into membrane using semidry transfer unit (Trans-Blot 
Turbo Transfer system, Bio-Rad, SA)). Activate Polyvinylidene fluoride (PVDF) 
transfer membrane (Immuno-Blot PVDF Membrane for Protein Blotting, Bio-Rad, 
SA) in 100% methanol for 30 seconds then in transfer buffer. Prepare sandwich 
transfer carefully, pre-wet set of filters paper / PVDF membrane / gel / pre / wet set 
of filters paper and remove bubble using a roller. Place the sandwich carefully into 
transfer cassette and close it, then placed in transfer unit and switch on. Choose List 
/ Bio Rad / low molecular weight protein 5 minutes / run. Remove the membrane 
from transfer unit and rinse briefly with PBS-T. Check transfer of the protein by 
staining the membrane for 5 minutes with ponceau stain (light sensitive, mix 2.5 ml 
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of stain with 22.5 ml distilled water). Wash the membrane to remove stain three 
times with distilled water then block the membrane. 
 
6- Blocking and antibody probing 
Block the membrane for one hour at room temperature on the shaker with 5% non-
fat milk in PBS-T (dissolve 25 g milk powder in 500 ml PBS-T and filter it with filter 
paper (Whatman, Germany)). After blocking, incubate the membrane with primary 
antibody (mouse monoclonal anti-synaptophysin ab18008 Abcam, SA) at a dilution 
of 1:5000 in 5% non-fat milk overnight at 4°C on shaker. Next day wash in PBS-T 3 
times 10 minutes each, then incubate with secondary antibody (Goat Anti-Mouse IgG 
HRP conjugate, #170-6516, Bio-Rad, SA) at dilution 1:10000 in 5% non-fat milk 
solution. Incubate with secondary antibody for two hours at room temperature with 
gentile agitation on shaker. Afterthought washes in PBS-T three times. 
 
7- ECL detection 
Prepare detection reagents (Clarity Western ECL Substrate, Cat. #170-5060, Bio-
Rad, SA) mix 1ml of each one, first white bottle which is super signal stable peroxide 
then brown bottle which is super signal west Pico Luminal / Enhancer. Use forceps 
to remove membrane from PBS-T and place it in a clean dry transparency. Drop the 
prepared ECL detection solution on the membrane. After one minute, close the 
transparency and remove excess fluid. Stick a fleshy sticker on the protein marker 
where expect the protein band signal to appear then keep it detection cassette.  
In a dark room cut x-ray film (Agfar Healthcare, SA), and lay it on the membrane 
(without removing the transparency) for 1-3 minutes. Take the x-ray film and 
immerse it in the developer solution and remove it once the band signal coming up 
Rinse briefly in water then immerse it in the fixer solution for 2 minutes then rinse in 





8- Stripling and re-probing of the membrane 
The purpose of stripling of the membrane is to incubate it with other antibody to 
detect other protein or for loading control. Immediately after ECL detection process 
wash the membrane shortly with PBS-T then with distilled water 2 times for 10 
minutes each. Wash with stripling buffer for 5 minutes then in distilled water two 
times for 10 minutes each finally wash briefly with PBS-T.  
Block the membrane with 5% non-fat milk for 1 hour at room temperature then 
incubate with housekeeping primary antibody (Monoclonal Anti-alpha-tubulin 
antibody produced in mouse, T5168, Sigma -Aldrich, SA) at dilution of 1:3000 in 5% 
non-fat milk in PBS-T overnight at 4°C. Wash with PBS-T 3 times 10 minutes each. 
Incubate with horseradish peroxidase (HRP) conjugated secondary antibody (Goat 
Anti-Mouse IgG-HRP conjugate, # 170-6516, Bio-Rad, SA) at room temperature on 
the shaker. Wash three times with PBS-T 10 minutes each and proceed to ECL 
detection as that for protein of interest. 
 
9- Scanning and analysis 
Scan the x-ray film with scanner and analyse with image J software (NIH, USA) as 
following steps: 
1- Open scanned image in image J software. Change the image to 8-bit mode, go to 
image / type / 8bit.  
2-Using rectangular tool from the image J toolbar draw rectangle shape around the 
first band, then go analyse / gel / select first lane, then drag the rectangle over the 
next band, go analyse / gel / select next lane, repeat this step until all bands are 
selected. 
4- Once all the bands selected go analyse / gel / plot lanes to give a profile plot for 
each lane. The profile plot represents the mean density of each lane; higher peak 
represents dark band while wider peak represents large band size. Choose the 
straight-line tool from image J toolbar and draw a line at the base of the peak to 
enclose the peak. Select wand tool from image J toolbar and click inside the peak 
and highlight all the peaks.  
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5- Choose analyse / gel / label peaks, the results are expressed as a percentage of 
the mean density of all the bands representing the protein of interest. Copy the result 
to excel datasheet.  
6- Same steps (1-6) needed for the housekeeping protein.  
7- Calculate the relative density of each band by dividing the percentage value of the 
mean density of the protein of interest (synaptophysin) over the percentage value of 
the mean density of the protein of housekeeping protein (alpha tubulin). 
 
 
 
 
 
 
